Argenx SE income statement

In fiscal 2025, Argenx SE reported revenue of $4.15bn, up 89.9% on the year before, operating income of $1.05bn (a 25.4% margin) and net income of $1.29bn, or $19.57 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Argenx SE: income statement, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	8	16	41	21	78	41	497	401	1,191	2,186	4,151
Cost of revenue	—	—	—	—	—	—	—	29	118	227	451
Gross profit	—	—	—	—	—	—	—	371	1,073	1,959	3,701
Research and development	—	—	—	84	221	371	581	663	859	983	1,364
Operating income	−17	−24	−26	−82	−199	−478	−349	−720	−425	−22	1,054
Interest expense	—	—	—	—	0	0	0	1	1	2	3
Income before tax	—	—	—	—	−176	−605	−400	−729	−304	85	1,279
Income tax	—	—	—	—	5	3	9	−20	−9	−748	−13
Net income	−17	−24	−32	−67	−181	−608	−408	−710	−295	833	1,292
Diluted EPS	—	—	—	—	−$4.69	−$13.40	−$7.99	−$13.05	−$5.16	$12.78	$19.57
Diluted shares (average)	16m	19m	25m	33m	39m	45m	51m	54m	57m	65m	66m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ARGX vs NBIX ARGX vs BMRN ARGX vs BNTX ARGX vs INCY

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Argenx SE's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Argenx SE.